Celgene beats Street

Celgene Corp. (NASDAQ:CELG) reported 2Q10 non-GAAP diluted EPS of $0.69, beating by $0.03 the Street's estimate of $0.66 and up 50% from $0.46 in 2Q09. Revenue rose 36% to $852.7 million. Sales of Revlimid lenalidomide for multiple myeloma (MM) and myelodysplastic syndromes (MDS) rose 48% to $587.1 million. ...